Clinical and technical feasibility of ultra-boost irradiation in dominant intraprostatic Lesion by Tomotherapy: Preliminary experience and revision of literature

Panminerva Medica

Volumn 58, Issue 1, 2016, Pages 16-22

  Garibaldi, Elisabetta ^a   Delmastro, Elena ^a   Gabriele, Domenico ^b   Bresciani, Sara ^a   Russo, Filippo ^a   Di Dia, Amalia ^a   Cattari, Gaetano ^a   Belli, Gabriella ^a   Gabriele, Pietro ^a  

^a FPO IRCCS   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Feasibility studies; Prostatic neoplasms; Radiotherapy, intensity modulated

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; AGED; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ITALY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL; SEMINAL VESICLE; TIME FACTOR; TREATMENT OUTCOME;

AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; HUMANS; ITALY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; SEMINAL VESICLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84992650294     PISSN: 00310808     EISSN: 18271898     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Pollack a, Zagars GK, Starkschall G, antolak Ja, Lee JJ, Huang e et al. Prostate cancer radiation dose response: Results of the m. d. anderson phase iii randomized trial. int J radiat Oncol Biol Phys 2002;53:1097-105
2. Zietman aL, deSilvio mL, Slater Jd, rossi cJ Jr, miller dW, adams Ja et al. comparison of conventional dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. Jama 2005;294:1233-9
3. Peeters ST, Heemsbergen Wd, Koper Pc, van Putten WL, Slot a, dielwart mF et al. dose-response in radiotherapy for localized prostate cancer: Results of the dutch multicenter randomized Phase iii trial comparing 68 Gy of radiotherapy with 78 Gy. J clin Oncol 2006;24:1990-6
4. dearnaley dP, Jovic G, Syndikus i, Khoo v, cowan ra, Graham Jd et al. escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the mrc rT01 randomised controlled trial. Lancet Oncol 2014;15:464-73
5. Zelefsky mJ, Leibel Sa, Gaudin PB, Kutcher GJ, Fleshner ne, venkatramen eS et al. dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. int J radiat Oncol Biol Phys 1998;41:491-500
6. Hanks Ge, Hanlon aL, epstein B, Horwitz em. dose response in prostate cancer with 8-12 years' follow-up. int J radiat Oncol Biol Phys 2002;54:427-35
7. eade Tn, Hanlon aL, Horwitz em, Buyyounouski mK, Hanks Ge, Pollack a. What dose of external-beam radiation is high enough for prostate cancer?. int J radiat Oncol Biol Phys 2007;68:682-9
8. alicikus Za, Yamada Y, Zhang Z, Pei X, Hunt m, Kollmeier m et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. cancer 2011;117:1429-37
9. Zelefsky mJ, Levin eJ, Hunt m, Yamada Y, Shippy am, Jackson a et al. incidence of late rectal and urinary toxicities after threedimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. int J radiat Oncol Biol Phys 2008;70:1124-9
10. Xu n, rossi PJ, Jani aB. Toxicity analysis of dose escalation from 75.6 Gy to 81.0 Gy in prostate cancer. am J clin Oncol 2011;34:11-5
11. Zelefsky mJ, chan H, Hunt m, Yamada Y, Shippy am, amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-9
12. Kupelian Pa, Willoughby Tr, reddy ca, Klein ea, mahadevan a. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. int J radiat Oncol Biol Phys 2007;68:1424-30
13. Pickett B, vigneault e, Kurhanewicz J, verhey L, roach m. Static ield intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven ield 3-dimensional radiotherapy. int J radiat Oncol Biol Phys 1999;44:921-9
14. van Lin en, Fütterer JJ, Heijmink SW, van der vight LP, Hoffmann aL, van Kollenburg P et al. imrT boost dose planning on dominantintraprostatic lesions: Gold marker-based three-dimensional fusion of cT with dynamic contrast-enhanced and 1H-spectroscopic mri. int J radiat Oncol Biol Phys 2006;65:291-303
15. cellini n, morganti aG, mattiucci Gc, valentini v, Leone m, Luzi S et al. analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning. int J radiat Oncol Biol Phys 2002;53:595-9
16. Xia P, Pickett B, vigneault e, verhey LJ, roach m 3rd. Forward or inversely planned segmental multileaf collimator imrT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. int J radiat Oncol Biol Phys 2001;51:244- 54
17. Pucar d, Hricak H, Shukla-dave a, Kuroiwa K, drobnjak m, eastham J et al. Clinically signiicant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence. int J radiat Oncol Biol Phys 2007;69:62-9
18. Borren a, Groenendaal G, moman mr, Boeken Kruger ae, van diest PJ, van vulpen m et al. accurate prostate tumour detection with multiparametric magnetic resonance imaging: Dependence on histological properties. acta Oncol 2014;53:88-95
19. Borren a, moman mr, Groenendaal G, Boeken Kruger ae, van diest PJ, van der Groep P et al. Why prostate tumour delineation based on apparent diffusion coeficient is challenging: An exploration of the tissue microanatomy. acta Oncol 2013;52:1629-36
20. Groenendaal G, van vulpen m, Pereboom Sr, Poelma-Tap d, Korporaal JG, monninkhof e et al. The effect of hormonal treatment on conspicuity of prostate cancer: Implications for focal boosting radiotherapy. radiother Oncol 2012;103:233-8
21. chang JH, Joon dL, Lee ST, Gong SJ, Scott am, davis ID et al. Histopathological correlation of (11)c-choline PeT scans for target volume deinition in radical prostate radiotherapy. Radiother Oncol 2011;99:187-92
22. Daşu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. clin Oncol (r coll radiol) 2007;19:289- 301
23. international commission on radiation Units and measurements (icrU). Prescribing, recording and reporting Photon Beam Therapy, icrU report 62. Prescribing, recording, and reporting Photon- Beam intensity-modulated radiation Therapy (imrT), icrU report 83
24. Bentzen Sm, constine LS, deasy JO, eisbruch a, Jackson a, marks LB et al. Quantitative analyses of normal Tissue effects in the clinic (QUANTEC): An introduction to the scientiic issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9
25. cox Jd. Toxicity criteria of the radiation Therapy Oncology Group (rTOG) and the european Organization for research and Treatment of cancer (eOrTc)." int J radiat Oncol Biol Phys. 1995 mar 30;31:1341-6
26. Bauman G, Haider m, van der Heide Ua, ménard c. Boosting imaging deined dominant prostatic tumors: A systematic review. Radiother Oncol 2013;107:274-81
27. riches SF, Payne GS, desouza nm, dearnaley d, morgan va, morgan Sc et al. effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional mr parameters. Br J radiol 2014;87:1037-40
28. murray LJ, Lilley J, Thompson cm, cosgrove v, mason J, Sykes J et al. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions. int J radiat Oncol Biol Phys 2014;89:406-15
29. crook J, Ots a, Gaztañaga m, Schmid m, araujo c, Hilts m et al. Ultrasound-planned high-dose-rate prostate brachytherapy: Dose painting to the dominant intraprostatic lesion. Brachytherapy 2014;13:433-41
30. maggio a, Fiorino c, mangili P, cozzarini c, de cobelli F, cattaneo Gm et al. Feasibility of safe ultra-high (eQd(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (diLs) by Helical Tomotheraphy. acta Oncol 2011;50:25-34
31. Fellin F, azzeroni r, maggio a, Lorentini S, cozzarini c, di muzio n et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: A treament planning comparison. radiother Oncol 2013;107:207-12
32. azzeroni r, maggio a, Fiorino c, mangili P, cozzarini c, de cobelli F et al. Biological optimization of simultaneous boost on intraprostatic lesions (diLs): Sensitivity to TcP parameters. Phys med. 2013;29:592-8
33. Kim Y, Hsu ic, Lessard e, Kurhanewicz J, noworolski Sm, Pouliot J. class solution in inverse planned Hdr prostate brachytherapy fordose escalation of DIL deined by combined MRI/MRSI. radiother Oncol 2008;88:148-55
34. Housri n, ning H, Ondos J, choyke P, camphausen K, citrin d et al. Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer. int J radiat Oncol Biol Phys 2011;80:614-20
35. abdellatif a, craig J, Jensen m, mulligan m, mosalaei H, Bauman G et al. experimental assessments of intrafractional prostate motion on sequential and simultaneous boost to a dominant intraprostatic lesion. med Phys 2012;39:1505-17